Eikon Therapeutics is a biotechnology company that develops gene therapies for the treatment of genetic diseases. The company's platform technology is based on CRISPR/Cas9 gene editing and synthetic biology. Eikon Therapeutics was founded in 2018 by a team of scientists from the University of California, Berkeley and the University of California, San Francisco. The company is backed by leading venture capital firms and has partnerships with academic institutions and pharmaceutical companies. Eikon Therapeutics is focused on developing therapies for rare genetic diseases and has a pipeline of preclinical programs.